Investor Relations
Overview

Altus® is focused on developing and commercializing novel protein therapeutics for patients with chronic gastrointestinal and metabolic diseases. Altus' in-depth knowledge of protein crystallization has resulted in a proprietary pipeline of orally-delivered and injectable protein replacement products. As a company, we are committed to improving the quality of life of patients.

Altus is developing a broad portfolio of products based on its novel protein crystallization technology. The company has the potential to redefine the use of biopharmaceutical proteins for chronic gastrointestinal or metabolic diseases by allowing the oral and parenteral delivery of high value protein replacement products. Altus has talented employees with a clear vision for the future, a vision that is committed to developing high quality products to benefit the well-being of people with unmet medical needs.

Recent Releases

Aug 4, 2009
Altus Pharmaceuticals Reports Second Quarter 2009 Financial Results

Jun 10, 2009
Altus Pharmaceuticals Reports Dosing First Patient in a Phase 2 Trial of ALTU-238 for Pediatric Growth Hormone Deficiency

May 11, 2009
Altus Pharmaceuticals Reports First Quarter 2009 Financial Results

more »

Events

May 11, 2009
Altus Pharmaceuticals First Quarter Results Conference Call

Mar 11, 2009
Altus Pharmaceuticals Fourth Quarter Results Conference Call

more »

Articles

Apr 1, 2008
Trying to Replace Animal-Derived Drugs

© 2009 Altus Pharmaceuticals Inc. All Rights Reserved | Terms and Conditions | Privacy Policy | Contact Us

 

This website contains certain “forward-looking” statements. These statements are based on the current estimates and assumptions of Altus Pharmaceuticals Inc. (“Altus” or “the Company”) as of the date of this presentation and are subject to uncertainties and changes in circumstances. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Actual results may vary materially from the expectations contained herein. When used herein, the words “may”, “will”, “should”, “could”, “would”, “plan”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “potential” and “expect” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Altus to be materially different from those reflected in such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings “Special Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company's most recent annual or quarterly filing with the Securities and Exchange Commission , as well as those set forth in the Company's other filings with the Securities and Exchange Commission. Except to the extent required by applicable securities laws, Altus is not under any obligation to (and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future events, or otherwise. All statements or materials contained on a page of this website are made only as of the date of revision set forth on that page.







© 2010 Altus Pharmaceuticals Inc. All Rights Reserved | Terms and Conditions | Privacy Policy | Contact Us | Site Map | Search